Based on the above evidence, GLP1-receptor agonists (lixisenatide, liraglutide, semaglutide, exenatide and dulaglutide) may be considered for patients with DM and HF as class IIb, level of evidence A [76]. The gene discussed is GLP1R; the disease is diabetes mellitus.